Since bromodomain and extraterminal (BET) proteins (such as BRD2 and BRD4) regulate MYC‐dependent transcription, various potent and selective small‐molecule inhibitors of these proteins have been developed and clinical trials are currently ongoing in hematological malignancies [32]. Here, MYC is linked to hematologic disorder.